Difference between revisions of "Team:NCTU Formosa/Design"

APOllO E.Cotector

To help doctors with innovated methods to judge whether to use monoclonal antibody targeted drugs more directly ,we redesigned the FDA approved monoclonal antibody targeted drugs, such as Bevacizumab (Avastin^® anti-VEGF)^[1], Cetuximab (Erbitux^® anti-EGFR)^[2] and Trastuzumab (Herceptin^® anti-HER2)^[3] into recombinant antibodies : scFv (single chain variable fragment). For detecting the specific molecules ("targeted molecules"), which are specific to these scFv of targeted drugs, scFv are displayed on the surfaces of E.coli by using a transmembrane fusion protein, Lpp-OmpA^[5] respectively; that is one APOllO E.Cotector displays one kind of targeted drugs of scFv each time. Take an example, while the anti-EGFR scFv (originate from Cetuximab) is displayed on the surface of E.coli, we can detect EGFR by this APOllO E.Cotector. Furthermore, as APOllO E.Cotector expressed fluorescence protein at the same time, the specific molecules ("targeted molecules") that correspond to those scFv of targeted drugs can be identified individually in direct by those different colors APOllO E.Cotector. In a simple word, because of the APOllO E.Cotector that display scFv of targeted drugs can we identify the corresponding specific molecules ("targeted molecules") ,then achieve to offer a prescription of monoclonal antibody targeted drug in direct .

The introduction of scFv

scFv is a fusion protein of the variable regions of the heavy chains(VH) and light chains (VL) of antibody connected by a flexible linker peptide. scFv still reserve completely functional antigen-binding fragment and specificity of the original immunoglobulin; that is , the property of specificity of antibody to antigen has being maintained. Moreover, scFv is only 20 percent the size as antibody ^[4], therefore it will not cause stress to E.coli for displaying it